Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06255379 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Mar 22, 2024 to May 6, 2024v3
  2. Start date: Feb 18, 2024 to Mar 22, 2024
    • Primary and study completion dates: Feb 18, 2027 to Mar 21, 2027
    • Secondary endpoints revised (4)
    • Study title shortened, about 11 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an Open, Single-arm, Multicenter, Prospective Phase II Study of Fuquinitinib Combined With Tegafur Gimeracil Oteracil in the Third-line Treatment of Patients With Advanced Metastatic CRC
Trial Details
NCT Number NCT06255379
Lead Sponsor Guangzhou University of Traditional Chinese Medicine
Conditions
(from sponsor)		 Metastasis Colorectal Cancer, Colon Cancer, Rectal Cancer
Related terms Colonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov